Back to Authors

Wang, Dingzhi

0009-0006-3802-4114

Mayo Clinic

Medical University of South Carolina

Citations 3

PPARδ Mediates the Effect of Dietary Fat in Promoting Colorectal Cancer Metastasis
Wang, Dingzhi , Fu, Lingchen, Wei, Jie , Xiong, Ying , DuBois, Raymond N.

Cancer Research | June 25, 2019 | Volume: 79 | Issue: 17 | Pages: 4480-4490

10.1158/0008-5472.can-19-0384 Get It

Abstract The nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPARδ) is a ligand-dependent transcription factor involved in fatty acid metabolism, obesity, wound healing, inflammation, and cancer. Although PPARδ has been shown to promote intestinal adenoma formation and growth, the molecular mechanisms underlying the contribution of PPARδ to colorectal cancer remain unclear. Here, we demonstrate that activation of PPARδ induces expansion of colonic cancer stem cells (CSC) and promotes colorectal cancer liver metastasis by binding to the Nanog promoter and enhancing Nanog expression. Moreover, PPARδ mediated the effect of a high-fat diet in promoting liver metastasis and induction of colonic CSC expansion. Our findings uncover a novel role of dietary fats in colorectal cancer metastasis and reveal novel mechanisms underlying PPARδ-mediated induction of CSCs and those responsible for the contribution of dietary fats to colorectal cancer progression. These findings may provide a rationale for developing PPARδ antagonists to therapeutically target CSCs in colorectal cancer. Significance: These findings show that PPARδ contributes to colorectal cancer metastasis by expanding the CSC population, indicating that antagonists that target PPARδ may be beneficial in treating colorectal cancer.
CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer
Wang, Dingzhi , Sun, Haiyan , Wei, Jie , Cen, Bo , DuBois, Raymond N.

Cancer Research | April 28, 2017 | Volume: 77 | Issue: 13 | Pages: 3655-3665

10.1158/0008-5472.can-16-3199 Get It

Abstract Emerging evidence suggests that the primary tumor influences the development of supportive metastatic microenvironments, referred to as premetastatic niches, in certain distant organs before arrival of metastatic cells. However, the mechanisms underlying the contributions of the primary tumor to premetastatic niche formation are not fully understood. Here, we demonstrate that colorectal carcinoma cells secrete VEGFA, which stimulates tumor-associated macrophages to produce CXCL1 in the primary tumor. Elevation of CXCL1 in premetastatic liver tissue recruited CXCR2-positive myeloid-derived suppressor cells (MDSC) to form a premetastatic niche that ultimately promoted liver metastases. Importantly, premetastatic liver-infiltrating MDSCs induced tumor cell survival without involvement of innate or adaptive immune responses. Our study provides the first evidence that primary malignant cell-secreted VEGFA stimulates tumor-associated macrophages to produce CXCL1, which recruits CXCR2-positive MDSCs to form a premetastatic niche to promote liver metastases. Our findings not only shed light on how the tumor microenvironment contributes to premetastatic niche formation at distant sites, but they also provide comprehensive insights into how MDSCs are recruited to other organs where they contribute to metastatic spread of disease. Moreover, our work also provides a rationale for development of CXCR2 antagonists to inhibit or prevent metastatic spread of disease. Cancer Res; 77(13); 3655–65. ©2017 AACR.
Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growth
Wang, Dingzhi , Fu, Lingchen, Guo, Lixia , Chaturvedi, Rupesh , Wilson, Keith T. , Wei, Ning , Sun, Xiaofei , Dey, Sudhansu K. , DuBois, Raymond N.

Proceedings of the National Academy of Sciences | April 25, 2014 | Volume: 111 | Issue: 19 | Pages: 7084-7089

10.1073/pnas.1324233111 Get It

Significance Our study not only reveals a novel role of peroxisome proliferator-activated receptor δ (PPARδ) in colonic inflammation and colitis-associated tumorigenesis, but also provides some rationale for development of PPARδ antagonists as new therapeutic agents in the treatment of inflammatory bowel disease and colitis-associated colorectal cancer. Moreover, our findings indicate that prostaglandin E 2 generated by chronic inflammation is a crucial mediator connecting chronic inflammation and colorectal carcinogenesis.